MAP Pharmaceuticals, Inc.
2400 Bayshore Parkway
Suite 200
Mountain View,
CA 94043-1107
United States - Map
Phone: 650-386-3100
Fax: 650-386-3101
Web Site: http://www.mappharma.com
| MAP Pharmaceuticals, Inc., a development stage company, focuses on developing drug candidates to treat local respiratory and treatable diseases. It develops inhalable drug particles to facilitate pulmonary delivery. The company’s proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of pediatric asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. Its product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. The company has a research and development, license, and supply agreement with Eiffel Technologies Limited to develop certain methods for manufacturing formulations of beta-agonists, alone or with steroid, steroids, or insulin; and a license agreement with Nektar Therapeutics UK Limited to develop and commercialize various formulations of a form of dihydroergotamine for administration by inhalation using a device. MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Timothy S. Nelson , 44
Chief Exec. Officer, Pres |
$
547.00K | N/A | Dr. Thomas A. Armer Ph.D., 54
Co-Founder, Chief Scientific Officer |
$
385.00K | N/A | Mr. Christopher Y. Chai , 42
Chief Financial Officer and Principal Accounting Officer |
$
325.00K | N/A | Dr. Stephen B. Shrewsbury M.B., Ch.B., 51
Consultant |
$
394.00K |
$
785.00K | Mr. Anastasios E. Gianakakos M.Sc., MBA, 35
Sr. VP of Corp. & Bus. Devel. |
$
309.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.83% Nasdaq 0.00%
Profile
